From: Nanomedicine review: clinical developments in liposomal applications
References | Disease | LF | Toxicitya Grade 3–5 (%) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
N | A | T | L | Na | D | V | P | Ast | |||
Wang and Zhang (2014) | NSCLC | L-PTX + carboplatin | 13 | 57 | |||||||
Lu et al. (2015) | NSCLC | L-PTX + gemcitabine + carboplatin | 14 | 4 | 2 | 2 | 4 | 2 | |||
Ahn et al. (2014) | NSCLC | Genexol-PM + gemcitabine | 16 | 3 | 7 | ||||||
Ignatiadis et al. (2016) | BC | EndoTAG-1 + paclitaxel + fluorouracil + epirubicin + cyclophosphamide | 7 | ||||||||
Awada et al. (2014) | TNBC | EndoTAG-1 + paclitaxel | 22 | 2 | 7 | 2 | 2 | 6 | |||
EndoTAG-1 | 5 | 2 | 2 | 4 | 5 | ||||||
Lu et al. (2016) | AGC | L-PTX + capecitabine | 2.9 | 17.6 | |||||||
Xu et al. (2013) | MGC | Lipusu® | 3 | 7 | 3 | 3 | |||||
Haas et al. (2012) | APC | EndoTAG-1 + gemcitabine | 12 | 8 | 10 | 2 | |||||
16 | 4 | 16 | 12 | 6 | |||||||
22 | 8 | 14 | 10 | 6 | 4 | 8 | |||||
Graziani et al. (2017)b | EOC | PTX–LCN | |||||||||
Strieth et al. (2013)c | HNC | EndoTAG-1 | |||||||||
Slingerland et al. (2017)d | AC | LEP-ETU | 17 | 3 |